— Український інформаційний портал урологів
(Украинский информационный портал урологов)

О проекте
О нас
Конференции и симпозиумы
Реформы и предложения
Нормативные документы
Наши партнеры

Информация для пациентов

Консультации уролога

Ассоциация урологов Украины
Сайт Института урологии Академии медицинских наук Украины
Европейская Ассоциация Урологов - Урологический информационный портал — исследователь урологии
Удовлетворительная ли у Вас зарпата? Какую Вы бы хотели иметь зарлату?
Как Вы оцениваете уровень медицины в Украине (10 баллов максимум)

Blood type О is significantly associated with a decreased risk of biochemical recurrence after radical prostatectomy Версия для печати Отправить на e-mail

Ohno Y., Ohori М., Nakashima J., Okubo H., Takizawa I., Nakagami Y., Satake N., Yoshioka K., Tachibana M.

Tokyo Medical University, Dept, of Urology, Tokyo, Japan

INTRODUCTION & OBJECTIVES: Recent studies have demonstrated associations among the ABO blood group, risk, and prognosis in various diseases. However, to date, few studies have investigated the prognostic significance of the ABO blood group in prostate cancer. The aim of this study was to investigate the association of the ABO blood group with biochemical recurrence (BCR) after radical prostatectomy (RP).

MATERIAL & METHODS: A total of 555 Japanese patients with T1-3N0M0 prostate cancer who underwent RP at our institution between 2004 and 2010 were studied. No patients received neoadjuvant and/or adjuvant therapy. The associations among the ABO blood group, clinicopathologic factors, and BCR were analysed using univariate and multivariate analyses. Hazard ratio (HR) and 95% confidence interval (Cl) for BCR according to the ABO blood group were calculated.

RESULTS: With a mean follow-up period of 52.0 months, 166 patients (29.9%) experienced BCR, with a 5-year BCR-free rate of 67.3%. Among the clinicopathologic characteristics, only surgical margin status was observed to significantly differ between patients with different ABO blood groups. The percentage of patients with a positive surgical margin was 41.9% for blood type A, 55.9% for type B, 46.7% for type O, and 35.4% for type AB (A vs. В, P = 0.023; AB vs. В, P = 0.016). In univariate analyses, a higher serum prostate-specific antigen (PSA) level at diagnosis, extracapsular extension, a positive surgical margin, seminal vesicle invasion, lymphovascular invasion, and a higher Gleason score (GS > 8) in the RP specimen were significantly associated with BCR. Although not a significant factor in univariate analysis (P = 0.113), the ABO blood group, in addition to the serum PSA level, extraprostatic extension, positive surgical margin, and Gleason score, was an independent predictor of BCR in multivariate analysis. Blood type О patients demonstrated a significantly lower risk of BCR than type A patients (HR, 0.653; 95%CI, 0.443-0.963; P = 0.031).

CONCLUSIONS: The ABO blood group was significantly associated with BCR in prostate cancer patients who underwent RP. In particular, this study suggests that blood type О is significantly associated with a decreased risk of BCR after RP. Further studies are needed to clarify the nature of this association.

  1. See EAU Guidelines on Prostate Cancer, for background, Prostate Cancer LR.pdf
  2. (

Please mention the EUROPEAN ASSOCIATION OF UROLOGY CONGRESS in any press stories

This abstract is embargoed to match the time of a poster presentation at the congress.

For more information, please contact the EAU press officer, Tom Parkhill, via tom(a) or via telephone number +39 349 238 8191

Dr Prasanna Sooriakumaran can be reached via Этот адрес e-mail защищен от спам-ботов. Чтобы увидеть его, у Вас должен быть включен Java-Script

The 29th EAU Congress takes place in Stockholm, Sweden, from 11th to 15th April, 2014. This is the largest and most important urology congress in Europe, with up to 13,000 expected to attend. Conference website:

Последнее обновление ( 07.05.2014 )
< Пред.   След. > - Український інформаційний портал урологів (Украинский информационный портал урологов) © 2018